Could a common supplement help a rare disease? early trial begins
Disease control
Recruiting now
This early-stage trial is testing the safety of a dietary supplement called NMN in 8 people with a rare genetic disorder known as DHDDS-CDG, which affects movement and development. Participants will take 250 mg of NMN daily for 6 months, with an optional 12-month follow-up. The m…
Phase: PHASE1 • Sponsor: Eva Morava-Kozicz • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC